Clinical Trial Update: Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial of IC351 in female Systemic Sclerosis patients with Raynaud's phenomenon and sexual dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• IC351

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED